Summary: The second patent, SE 543880, was granted in Sweden and relates to controlling the temperature of the dispensing nozzle during the 3D bioprinting leading to increased printing consistency, less downtime due to clogging, and less material waste. BICO believes 3D bioprinting will help accelerate drug development and eventually alleviate the strain on organ transplants and this patent is an important milestone in that mission. The two patents strengthen the companys protection for intellectual properties and complement a full portfolio of solutions being developed by BICO and its subsidiary CELLINK.
BICO, an expert bio convergence company, has been granted two patents relating to the regulation and control of temperatures in 3D Bioprinters. The first patent, US 11,046,001, was granted in the United States and relates to the temperature regulation of bioinks which allows for better cell viability during 3D bioprinting. The second patent, SE 543880, was granted in Sweden and relates to controlling the temperature of the dispensing nozzle during the 3D bioprinting leading to increased printing consistency, less downtime due to clogging, and less material waste.
"Our mission at BICO is to create the future of medicine and improve health globally through the convergence of key biotechnologies", explained Erik Gatenholm, CEO and Co-Founder of BICO. "This innovation will help our incredible customers drive advancements across drug discovery, tissue engineering, and disease modeling." BICO believes 3D bioprinting will help accelerate drug development and eventually alleviate the strain on organ transplants and this patent is an important milestone in that mission. It is vital during the printing process to maintain a constant temperature to keep cells alive at 37 degrees Celsius. Temperature control is also very helpful while using bioinks like Gelma and Collagen to avoid clogging the needles and nozzles. The two patents strengthen the company's protection for intellectual properties and complement a full portfolio of solutions being developed by BICO and its subsidiary CELLINK.
"At BICO we work tirelessly to consistently improve and innovate our bioprinting offerings", said Dr. Héctor Martínez, co-founder and Chief Technology Officer of BICO. "Our customers around the world are continuously pushing the limits of science using our technology and Im excited to see how they use these innovations to help make the world a healthier place." 3D bioprinting is an essential tool for the fabrication of soft materials, tissue models, and 3D cell culture environments. As the global 3D bioprinting leader, BICO and CELLINK have developed breakthrough technologies for biofabrication, including extrusion-based bioprinters, light-based bioprinters, live-cell imaging devices, inks, and accessories. The companys products are in more than 2,000 of the worlds most innovative labs including Stanford, Harvard, Merck, Novartis, AstraZeneca, Johnson & Johnson, and others.